ArticleBreast cancer (Dove Medical Press)2026
Plasma Vitamin C Levels in Distinguishing Benign from Malignant Breast Tumors and Clinical Correlates in Chinese Patients: A Cross-Sectional Study.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common malignancy in women globally, with rising incidence and earlier onset. Vitamin C, an essential micronutrient, plays critical roles in immune regulation and antioxidation, and cancer patients often exhibit lower plasma levels. Aim: To assess plasma vitamin C as a predictive biomarker for breast cancer and its clinical relevance. Methods: From January to July 2025, 115 patients with benign breast tumors and 131 breast cancer patients were enrolled. Inclusion criteria were age >18 years and no regular vitamin C supplementation in the prior three months. Exclusion criteria included recent high-dose vitamin C supplementation and pregnancy. Fasting blood samples were collected prior to surgery for benign tumor patients, and 21 days after discharge (immediately before the next chemotherapy cycle) for breast cancer patients. Plasma vitamin C concentrations were quantified using UPLC-MS/MS. Clinical data, including demographics, tumor characteristics, and treatment-related parameters, were recorded. Statistical analyses were performed using SPSS 27.0. Results: Plasma vitamin C concentrations were significantly lower in breast cancer patients (median 0.72 μg/mL) compared to benign tumor patients (mean 4.06 μg/mL). In benign patients, vitamin C levels negatively correlated with BMI. In breast cancer patients, vitamin C levels were significantly associated with TNM stage, pathological type, and number of metastatic sites. Hematocrit, platelet distribution width, triglycerides, and hemoglobin significantly correlated with plasma vitamin C levels. Patients receiving anthracycline-based chemotherapy had the lowest vitamin C levels, and severe adverse effects (grade ≥3) were linked to further reductions. Conclusion: Plasma vitamin C levels are significantly lower in breast cancer patients than in benign tumor cases, correlating with disease severity, chemotherapy regimens, and adverse effects. Our findings identify plasma vitamin C as a potential dual-utility biomarker for distinguishing malignant tumors and predicting chemotherapy-related toxicity, suggesting its therapeutic potential as a nutritional modulator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.